Skip to main content

Molecular Partners AG

MOLN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001745114

No open-market purchases or sales by Molecular Partners AG insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Molecular Partners AG changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of MOLN: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders015+15
Shares01.72M+1.72M
Value$0$35.1M+$35.1M

New holders (15)

Institutions that held Molecular Partners AG at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to MOLN in Q2 2021
InstitutionSharesValue% of portfolio
Suvretta Capital Management, LLC400,000$8.20M0.12%
Monashee Investment Management LLC250,000$5.12M0.61%
Federated Hermes, Inc.235,294$4.80M0.01%
Tudor Investment Corp Et Al175,033$3.59M0.07%
BlackRock Inc.165,038$3.38M0.00%
Hound Partners, LLC121,247$2.48M0.12%
Artal Group S.A.100,000$2.05M0.05%
Marshall Wace North America L.P.96,499$1.97M0.01%
Millennium Management LLC68,145$1.39M0.00%
Caas Capital Management LP60,000$1.23M0.07%
Capstone Investment Advisors, LLC28,741$589.0K0.01%
Old Mission Capital LLC14,781$303.0K0.01%
Morgan Stanley1,201$25.0K0.00%
Westchester Capital Management, LLC1,000$20.0K0.00%
UBS Group AG23$00.00%

Sold out (0)

Institutions that held Molecular Partners AG at the end of Q1 2021 and filed for Q2 2021 without it.

None.